The authors determined that KRAS knockout (KO) PDA cells had a striking up-regulation of major histocompatibility complex I (MHC I) genes compared with KRAS intact control cells, underlying increased susceptibility to anti-tumor immunity. The gene discussed is KRAS; the disease is Patent ductus arteriosus.